1 |
N4-behenoyl-1-beta-D-arabinofuranosylcytosine
(26 times)
|
Neoplasms (15 times)
|
ara-C (7 times) AML (4 times) CR (4 times)
|
1980 Pharmacologic and clinical studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
|
2 |
behenoyl ara-C
(5 times)
|
Antineoplastic Agents (3 times)
|
ACM-A (1 time) DNR (1 time) IDA (1 time)
|
1983 [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
|
3 |
Behenoyl cytosine arabinoside
(1 time)
|
Antineoplastic Agents (1 time)
|
AMP (1 time) CR (1 time) GW (1 time)
|
1994 Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
|
4 |
behenoyl-arabinofuranosylcytosine
(1 time)
|
Neoplasms (1 time)
|
ACM-A (1 time) DNR (1 time)
|
1986 Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
|
5 |
breath-hold CT AC
(1 time)
|
Cardiovascular Diseases (1 time)
|
AC (1 time) BH (1 time) CT (1 time)
|
2016 Real-time respiratory triggered SPECT myocardial perfusion imaging using CZT technology: impact of respiratory phase matching between SPECT and low-dose CT for attenuation correction.
|
6 |
breath-hold SPECT-MPI with AC
(1 time)
|
Cardiovascular Diseases (1 time)
|
AC (1 time) BH (1 time) CT (1 time)
|
2016 Real-time respiratory triggered SPECT myocardial perfusion imaging using CZT technology: impact of respiratory phase matching between SPECT and low-dose CT for attenuation correction.
|